KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Profit After Tax (2016 - 2025)

Rigel Pharmaceuticals has reported Profit After Tax over the past 16 years, most recently at $268.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 1769.22% year-over-year to $268.1 million; the TTM value through Dec 2025 reached $367.0 million, up 1999.08%, while the annual FY2025 figure was $367.0 million, 1999.08% up from the prior year.
  • Profit After Tax for Q4 2025 was $268.1 million at Rigel Pharmaceuticals, up from $27.9 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $268.1 million in Q4 2025 and troughed at -$27.4 million in Q1 2022.
  • A 5-year average of $14.1 million and a median of -$3.4 million in 2023 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: plummeted 169.48% in 2022 and later soared 5887.67% in 2025.
  • Year by year, Profit After Tax stood at -$22.6 million in 2021, then soared by 106.19% to $1.4 million in 2022, then crashed by 47.39% to $737000.0 in 2023, then surged by 1845.86% to $14.3 million in 2024, then skyrocketed by 1769.22% to $268.1 million in 2025.
  • Business Quant data shows Profit After Tax for RIGL at $268.1 million in Q4 2025, $27.9 million in Q3 2025, and $59.6 million in Q2 2025.